Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alnylam Switches Attention To Access After Onpattro EU Okay

Aug 31 2018

• By Kevin Grogan

old abacus with bills of 500 euros close up — Alnylam doing the sums for Onpattro in EU • Source: Shutterstock

Related Content

Interview: Alnylam President On Patisiran Lift-Off Plans

Nov 06 2017

Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade

Apr 25 2018

Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro

Aug 11 2018

Pfizer Has Tafamidis Data In Hand, But Market Development Still A Challenge

Aug 27 2018

Aimovig And Tegsedi In Raft Of Products To Get EMA Thumbs up

Jun 01 2018

Alnylam's Onpattro Carries Narrower hATTR Indication Without Cardiac Data

Aug 14 2018

Related Companies

Alnylam Pharmaceuticals Inc.

Ionis Pharmaceuticals, Inc.

Pfizer Inc.

Additional Topics

Europe Reimbursement Approvals Cardiovascular BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window